Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis

Mitsubishi Tanabe Pharma logo

Mitsubishi Tanabe Pharma

Status and phase

Completed
Phase 3

Conditions

Chronic Kidney Disease

Treatments

Drug: Placebo of MCI-196
Drug: Placebo of Simvastatin
Drug: MCI-196
Drug: Simvastatin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00858637
MCI-196-E11

Details and patient eligibility

About

The primary objective of this study is to demonstrate the superiority of MCI-196 over placebo and non-inferiority with simvastatin in reducing serum low-density lipoprotein (LDL)-cholesterol in subjects with chronic kidney disease Stage V on dialysis. This study incorporates a Washout Period and two treatment periods - an active comparison phase and a placebo-controlled withdrawal phase.

Enrollment

260 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female, and is >=18 years old
  • Stable hemodialysis or peritoneal dialysis
  • Subjects undergoing regular dialysis treatment
  • If Female and of child-bearing potential, have a negative serum pregnancy test
  • Male subjects must agree to use appropriate contraception

Exclusion criteria

  • Current clinically significant medical comorbidities, which may substantially compromise subject safety, or expose him/her to undue risk, or interfere significantly with study procedures and which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study
  • Serum albumin level < 30 g/L
  • Triglycerides level > 6.76 mmol/L (600 mg/dL)
  • LDL-cholesterol level > 4.94 mmol/L (190 mg/dL)
  • A History of significant gastrointestinal motility problems
  • Biliary obstruction or proven liver dysfunction
  • A positive test for HIV 1 and 2 antibodies
  • A history of substance or alcohol abuse within the last year
  • The subject has a history of rhabdomyolysis or myopathy
  • Schedule to receive a kidney transplant within the next 6 months
  • The subject has porphyria
  • Participation in a clinical study with any experimental medication in the last 30 days or an experimental biological product within the last 90 days prior to signing of informed consent

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

260 participants in 4 patient groups, including a placebo group

1 MCI-196
Experimental group
Treatment:
Drug: Placebo of Simvastatin
Drug: MCI-196
2 Placebo of MCI-196
Placebo Comparator group
Treatment:
Drug: Placebo of Simvastatin
Drug: Placebo of MCI-196
3 Simvastatin
Active Comparator group
Treatment:
Drug: Simvastatin
Drug: Placebo of MCI-196
4 Placebo of Simvastatin
Placebo Comparator group
Treatment:
Drug: Placebo of Simvastatin
Drug: Placebo of MCI-196

Trial contacts and locations

39

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems